Advice
following a full submission:
bempedoic acid (Nilemdo®) is not recommended for use within NHSScotland.
Indication under review: in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- In combination with a statin, or a statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated.
In four phase III studies, the percentage reduction in LDL-C to 12-weeks was significantly larger with bempedoic acid compared with placebo.
The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.
Medicine details
- Medicine name:
- bempedoic acid (Nilemdo)
- SMC ID:
- SMC2292
- Indication:
In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 December 2020